Altimmune Names Richard Menziuso VP & Principal Accounting Officer

What Happened
Altimmune, Inc. (ALT) filed an 8-K reporting that on September 24, 2026 its Board appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer, with the appointment effective September 29, 2026. Gregory Weaver will remain the Company’s Chief Financial Officer. The filing notes Mr. Menziuso has 28 years of finance and accounting experience and is a Certified Public Accountant (CPA) and Chartered Global Management Accountant (CGMA).

Key Details

• Appointment announced in an 8-K filed Sept 29, 2026; board action taken Sept 24, 2026; effective date Sept 29, 2026.
• Mr. Menziuso, age 51, has 28 years’ experience, including roles at Centessa Pharmaceuticals (VP, Corporate Controller), Thermo Fisher Scientific (North America Controller), Axovant Gene Therapies (VP, Accounting and Controller), and earlier positions at PwC and Bristol-Myers Squibb.
• Educational/professional credentials: B.B.A. in Public Accounting from Pace University; CPA and CGMA.
• Company will enter an indemnification agreement with Mr. Menziuso in the same form used for other executive officers; filing states no related-party transactions, no family relationships, and no other arrangements relevant to his appointment.

Why It Matters
This is an internal financial leadership appointment reported on Form 8-K. For investors, the change clarifies who will hold the Company’s principal accounting officer responsibilities (Mr. Menziuso) while the CFO, Gregory Weaver, remains in place—important for understanding who oversees financial reporting and controls. The filing indicates no related-party issues and includes the standard indemnification arrangement, suggesting this is a routine executive appointment rather than a change prompted by financial irregularities.